Print

Crimson Life Sciences Release: In-Vitro Diagnostics (IVD) Manufacturers at Risk for Device Reclassification  
3/20/2012 7:11:12 AM

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Crimson Life Sciences, a division of TransPerfect and the world’s only ISO 13485 and ISO 14971 certified translation provider, announced the latest installment of their Expert Opinion webinar series. On Tuesday, March 27 at 11:00 AM (Eastern Time), Crimson will host an informational webinar examining the serious risk classification repercussions of the upcoming In-Vitro Diagnostics Directive (IVDD) revision. Presented by Ms. Connie O’Connor, a Senior Project Manager and Notified Body auditor for DEKRA Certification, B.V. (formerly KEMA Quality), registration for this online event is free of charge.
//-->